San Francisco startup Structure Therapeutics is additionally engaged on an oral, after-daily GLP-one drug identified as GSBR-1290—the drug surpassed Wall Road’s anticipations in June each time a mid-phase review showed common weight loss of close to six% and it ideas to start A diffe